Market Insights Snapshot
In the realm of Tincture & Sublingual category, Amend Cannabis has demonstrated a consistent performance in Missouri, maintaining a top 3 position from July to October 2023. The brand peaked in September, securing the 2nd spot, which denotes a positive trend. However, the data for October shows a slight dip, with the brand falling back to the 3rd position. This could be indicative of increased competition or a shift in consumer preferences. It's important to note that the brand's sales have been on an upward trend, with October sales reaching approximately 46,516 units, a significant increase from July's 31,859 units.
When we turn our attention to the Topical category, the performance of Amend Cannabis in Missouri is somewhat less consistent. The brand maintained a position within the top 5 from July to October 2023, fluctuating between the 4th and 5th spots. While this is still a commendable achievement, the lack of upward movement could be a cause for concern. This is further compounded by the fact that sales in this category have been on a slight downward trend, with October sales falling to approximately 21,059 units, a decrease from July's 25,062 units. This data suggests that the brand may need to revisit its strategy in the Topical category.
In the Tincture & Sublingual category within Missouri, Amend Cannabis has shown a consistent performance, maintaining its position within the top three brands over the period from July to October 2023. Despite stiff competition from brands like Vivid (MO), Zen Cannabis, Vlasic Labs, and marQaha, Amend Cannabis managed to improve its rank from 3rd to 2nd in September 2023, only to return to the 3rd position in October. While the sales of Amend Cannabis have been consistently lower than those of Vivid (MO) and Zen Cannabis, it has consistently outperformed marQaha and Vlasic Labs. The sales trend for Amend Cannabis shows a steady increase over the observed period, indicating a positive market response despite the competitive landscape.
In October 2023, Amend Cannabis saw its CBD/THC 1:1 Tincture (100mg CBD, 100mg THC, 30ml) maintain its position as the top-performing product, with a remarkable sales figure of 1615 units. Following closely was the CBD/THC 1:1 Balm (50mg CBD, 50mg THC), which held steady at the second rank. The third spot was occupied by the CBD/THC/CBC 1:1 Transdermal Lotion (50mg CBD, 50mg THC, 50mg CBC), despite a drop in sales compared to previous months. The bottom two spots were consistently held by the CBD/THC 10:1 Tincture (1000mg CBD, 100mg THC, 30ml) and CBD/THC 4:1 Tincture (400mg CBD, 100mg THC), respectively. Overall, the rankings remained unchanged from the previous months, indicating a stable preference among Amend Cannabis customers.